Axogen Corporation

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Axogen Corporation sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 3 completed later-stage tilt top decile by trial count

Axogen Corporation: 10 sponsored US clinical trials, 1 recruiting.

Axogen Corporation sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 3 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cavernous Nerve Injury, with 1 trials.

Top-decile sponsor footprint

Axogen Corporation ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 4

A Prospective, Randomized, Assessor-Blinded, Multicenter Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction

NCT07657182
ACTIVE NOT RECRUITING NA

Nerve Protection Evaluation: Revision Cubital Tunnel Syndrome Decompression

NCT06117501
ACTIVE NOT RECRUITING NA

Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends

NCT04865679
ACTIVE NOT RECRUITING

Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction

NCT01526681
TERMINATED

Surgical Treatment of Chronic Neuropathic Pain

NCT04287075
TERMINATED

Registry of Avive® Soft Tissue Membrane Utilization in Selected Applications of Acute Trauma of the Upper Extremity

NCT03943134
COMPLETED NA

Study of AxoGuard® Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma Pain

NCT03940963
COMPLETED Phase 3

Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair

NCT01809002
COMPLETED Phase 4

Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer

NCT00953277
TERMINATED NA

A Comparative Post-marketing Study of Commercially Available Peripheral Nerve Gap Repair Options

NCT00948025

Phase Distribution

PhaseTrial count
Phase 3 1
Phase 4 2

Therapeutic Areas

Cavernous Nerve Injury 1
Chronic Nerve Pain 1
Symptomatic Neuroma 1
Recalcitrant Cubital Tunnel Syndrome 1
Recurrent Cubital Tunnel Syndrome 1
Nerve Reconstruction 1
Radical Prostatectomy 1
Peripheral Nerve Injury 1
Peripheral Nerve Injuries 1
Amputation 1

Where Axogen Corporation enrollment is open (later-stage tilt)

1 recruiting of 10 indexed (10% open); 3 completed (30%).

Phase mix: 3 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Cavernous Nerve Injury (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Axogen Corporation: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Axogen Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share Axogen CorporationAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)
Axogen Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Axogen Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Axogen Corporation page

10 registered trials is a research-attention snapshot, not an endorsement of Axogen Corporation or any single study.

  • 1 of Axogen Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cavernous Nerve Injury is the condition Axogen Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cavernous Nerve Injury trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Axogen Corporation pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.